journal article·2022-10-25Open access

Melimine-Modified 3D-Printed Polycaprolactone Scaffolds for the Prevention of Biofilm-Related Biomaterial Infections

Silvia Cometta, Robert T. Jones, Alfredo Juárez-Saldivar, Bogdan C. Donose, Muhammad Yasir, Nathalie Bock, Tim R. Dargaville, Karl Bertling, Michael Brünig, Aleksandar D. Rakić, Mark Willcox, Dietmar W. Hutmacher

ACS Nano· Volume 16· Issue 10

Abstract

Biomaterial-associated infections are one of the major causes of implant failure. These infections result from persistent bacteria that have adhered to the biomaterial surface before, during, or after surgery and have formed a biofilm on the implant’s surface. It is estimated that 4 to 10% of implant surfaces are contaminated with bacteria; however, the infection rate can be as high as 30% in intensive care units in developed countries and as high as 45% in developing countries. To date, there is no clinical solution to prevent implant infection without relying on the use of high doses of antibiotics supplied systemically and/or removal of the infected device. In this study, melimine, a chimeric cationic peptide that has been tested in Phase I and II human clinical trials, was immobilized onto the surface of 3D-printed medical-grade polycaprolactone (mPCL) scaffolds via covalent binding and adsorption. X-ray photoelectron spectroscopy (XPS) and time-of-flight secondary ion mass spectrometry (ToF-SIMS) spectra of melimine-treated surfaces confirmed immobilization of the peptide, as well as its homogeneous distribution throughout the scaffold surface. Amino acid analysis showed that melimine covalent and noncovalent immobilization resulted in a peptide density of ∼156 and ∼533 ng/cm2, respectively. Furthermore, we demonstrated that the immobilization of melimine on mPCL scaffolds by 1-ethyl-3-[3-(dimethylamino)propyl] carbodiimide hydrochloride (EDC) coupling and noncovalent interactions resulted in a reduction of Staphylococcus aureus colonization by 78.7% and 76.0%, respectively, in comparison with the nonmodified control specimens. Particularly, the modified surfaces maintained their antibacterial properties for 3 days, which resulted in the inhibition of biofilm formation in vitro. This system offers a biomaterial strategy to effectively prevent biofilm-related infections on implant surfaces without relying on the use of prophylactic antibiotic treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Bone Tissue Engineering Materials · Antimicrobial Peptides and Activities · Dental materials and restorations

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Faculty of Engineering, School of Mechanical, Medical and Process Engineering, Queensland University of Technology, Brisbane, QLD 4000, Australia

Australian Research Council Training Centre for Multiscale 3D Imaging, Modelling and Manufacturing (M3D Innovation), Queensland University of Technology, Kelvin Grove, QLD 4059, Australia

Max Planck Queensland Centre, Queensland University of Technology, Brisbane, QLD 4000, Australia

Central Analytical Research Facility (CARF), Queensland University of Technology, Brisbane, QLD 4000, Australia

Centre for Materials Science, School of Chemistry and Physics, Queensland University of Technology, Brisbane, QLD 4000, Australia

Unidad Académica Multidisciplinaria Reynosa Aztlán, Universidad Autónoma de Tamaulipas, Reynosa 88740, Mexico

School of Information Technology and Electrical Engineering, The University of Queensland, Brisbane, QLD 4072, Australia

School of Optometry and Vision Science, University of New South Wales, Sydney, NSW 2033, Australia

Faculty of Health, School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD 4000, Australia

Translational Research Institute, Woolloongabba, QLD 4102, Australia

Australian Research Council Industrial Transformation Training Centre in Additive Biomanufacturing, Queensland University of Technology, Brisbane, QLD 4059, Australia

Funding

Australian Research Council · Max Planck Queensland Centre

References (51)

Show source-provided references
1. 10.2106/JBJS.M.0147410.2106/JBJS.M.01474 ↗
2. 10.1016/j.tibtech.2015.09.00210.1016/j.tibtech.2015.09.002 ↗
3. 10.1126/scitranslmed.300452810.1126/scitranslmed.3004528 ↗
4. 10.1089/sur.2018.25810.1089/sur.2018.258 ↗
5. 10.1039/C7TB02445B10.1039/C7TB02445B ↗
6. 10.1038/nrmicro338010.1038/nrmicro3380 ↗
7. 10.1002/jbm.a.3209010.1002/jbm.a.32090 ↗
8. 10.1179/joc.2007.19.6.60910.1179/joc.2007.19.6.609 ↗
9. 10.1093/jac/dkw55610.1093/jac/dkw556 ↗
10. 10.1111/j.1365-2672.2008.03942.x10.1111/j.1365-2672.2008.03942.x ↗
11. 10.1167/iovs.12-1098910.1167/iovs.12-10989 ↗
12. 10.3390/molecules2517384310.3390/molecules25173843 ↗
13. 10.3390/antibiotics1010115910.3390/antibiotics10101159 ↗
14. 10.1088/1748-605X/ab5e1b10.1088/1748-605X/ab5e1b ↗
15. 10.1021/acsami.1c1769710.1021/acsami.1c17697 ↗
16. 10.1021/acs.molpharmaceut.8b0134510.1021/acs.molpharmaceut.8b01345 ↗
17. 10.1097/OPX.000000000000023210.1097/OPX.0000000000000232 ↗
18. Bendak A. · J. Islamic Acad. Sci. · 1991 · 4 · 275
19. Cools P. · 2019 · 3110.1002/9783527819249.ch2 ↗
20. 10.1088/1361-6463/aa748a10.1088/1361-6463/aa748a ↗
21. 10.3390/ma1311243510.3390/ma13112435 ↗
22. 10.1088/1361-6463/ac453910.1088/1361-6463/ac4539 ↗
23. 10.1002/ppap.20190016310.1002/ppap.201900163 ↗
24. 10.1016/S0142-9612(00)00121-610.1016/S0142-9612(00)00121-6 ↗
25. 10.1088/0957-4484/23/50/50571110.1088/0957-4484/23/50/505711 ↗
26. 10.1116/1.503050710.1116/1.5030507 ↗
27. 10.1016/j.biomaterials.2015.01.02510.1016/j.biomaterials.2015.01.025 ↗
28. 10.1016/j.bone.2021.11616310.1016/j.bone.2021.116163 ↗
29. 10.1366/0003702036062590710.1366/00037020360625907 ↗
30. 10.1366/14-0753810.1366/14-07538 ↗
31. 10.1038/ncomms389010.1038/ncomms3890 ↗
32. 10.1039/C9CP01987A10.1039/C9CP01987A ↗
33. 10.1016/j.ijantimicag.2010.02.00510.1016/j.ijantimicag.2010.02.005 ↗
34. 10.1116/1.502300510.1116/1.5023005 ↗
35. 10.1039/D0CS00181C10.1039/D0CS00181C ↗
36. 10.1016/j.actbio.2012.07.02910.1016/j.actbio.2012.07.029 ↗
37. 10.1007/s10856-011-4527-910.1007/s10856-011-4527-9 ↗
38. 10.1116/1.494249810.1116/1.4942498 ↗
39. 10.1021/nn103577g10.1021/nn103577g ↗
40. 10.1071/CH1812910.1071/CH18129 ↗
41. 10.1002/sia.540610.1002/sia.5406 ↗
42. 10.1016/j.actbio.2010.11.00510.1016/j.actbio.2010.11.005 ↗
43. 10.1016/j.biotechadv.2010.08.01210.1016/j.biotechadv.2010.08.012 ↗
44. 10.3389/fmicb.2019.0305310.3389/fmicb.2019.03053 ↗
45. 10.1007/s11595-017-1735-210.1007/s11595-017-1735-2 ↗
46. 10.1016/j.apsusc.2021.14960210.1016/j.apsusc.2021.149602 ↗
47. 10.1021/nl301159v10.1021/nl301159v ↗
48. 10.1002/anie.20150993710.1002/anie.201509937 ↗
49. 10.1093/nar/gkw32910.1093/nar/gkw329 ↗
50. 10.1186/s13321-021-00522-210.1186/s13321-021-00522-2 ↗
51. 10.1093/nar/gkv31510.1093/nar/gkv315 ↗